Objective: To assess the impact of low-to-moderate risk prostate cancer on patients' quality of life (QoL) at diagnosis and within the first year of treatment.
Subjects and Methods: Men (n = 672) aged 50-75 years with prostate cancer (Gleason score ≤ 7, PSA ≤ 20 ng/mL and clinical staging T1c-T2b) were enrolled in five European countries. Patients completed five questionnaires, including EORTC Quality of Life Questionnaire-Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire-Cancer 30 (QLQ-C30). Questionnaires were completed at baseline, at 3 months and 12 months after starting treatment. The primary endpoint was the change in QLQ-PR25 urinary symptoms subscale score from baseline to the assessment at 3 months.
Results: Mean (SD) age was 65.0 (5.7) years and 400 (66%) men had Gleason score ≤ 6 prostate cancer. The most frequently used initial treatment was radical prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (P < 0.001), indicating that urinary symptoms worsened after treatment. The score was lower at 12 months than at 3 months, but it was still significantly higher than at baseline (P < 0.001). Hormonal treatment-related symptoms, sexual functioning, and sexual activity scores significantly worsened at 3 and 12 months (all P < 0.001). For the QLQ-C30 questionnaire, global health status/QoL score significantly decreased at month 3 but was not different from baseline by month 12. Scales for physical, role, and social functioning, and fatigue, showed significant deterioration at 3 and 12 months.
Conclusions: Low-to-moderate risk prostate cancer may have a substantial effect on patients' QoL within one year following treatment.
Written by:
Selli C, Bjartell A, Burgos J, Somerville M, Palacios JM, Benjamin L, Black L, Castro R. Are you the author?
Department of Urology, University of Pisa, 56126 Pisa, Italy; Skåne University Hospital, SE 205 02 Malmö, Sweden; Hospital Ramon y Cajal, 28034 Madrid, Spain; GlaxoSmithKline, Research Triangle Park, NC 27709, USA; GlaxoSmithKline, Urology Centre of Excellence, C/Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain; GlaxoSmithKline, Health Outcomes Studies, 78160 Marly-Le-Roi, France; GlaxoSmithKline, King of Prussia, PA 19406, USA.
Reference: Prostate Cancer. 2014;2014:472949.
doi: 10.1155/2014/472949
PubMed Abstract
PMID: 24757567
UroToday.com Prostate Cancer Section
